POSC94 Cost-Effectiveness of Risdiplam Versus Nusinersen for Treating Patients with Spinal Muscular Atrophy Type 1 in China

Abstract

Authors

J Hu CS Sutherland V Aponte Ribero L Zhu X Hou Y Xia M Tang C Jin Q Kang

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×